UPLC-HR-MS/MS-based determination study on the metabolism of four synthetic cannabinoids, ADB-FUBICA, AB-FUBICA, AB-BICA and ADB-BICA, by human liver microsomes.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Biomedical chromotography

• Publication date

  2018-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/bmc.4113PMID 28992356
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vitro metabolism of a novel synthetic cannabinoid, EAM-2201, in human liver microsomes and human recombinant cytochrome P450s.

  2016cited by this paper
• In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201)

  2016cited by this paper
• In Vitro and In Vivo Human Metabolism of Synthetic Cannabinoids FDU-PB-22 and FUB-PB-22

  2016influential reference
• Strategies to distinguish new synthetic cannabinoid FUBIMINA (BIM-2201) intake from its isomer THJ-2201: metabolism of FUBIMINA in human hepatocytes

  2016influential reference
• In vitro, in vivo and in silico metabolic profiling of α-pyrrolidinopentiothiophenone, a novel thiophene stimulant.

  2016cited by this paper
• The drug situation in Europe: an overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015.

  2016cited by this paper
• In vitro elucidation of the metabolic profile of the synthetic cannabinoid receptor agonists JWH-175 and JWH-176

  2016cited by this paper
• Biotransformation of synthetic cannabinoids JWH-018, JWH-073 and AM2201 by Cunninghamella elegans.

  2016cited by this paper
• Synthetic cannabimimetic agents metabolized by carboxylesterases.

  2015cited by this paper
• Elucidation of the metabolites of the novel psychoactive substance 4-methyl-N-ethyl-cathinone (4-MEC) in human urine and pooled liver microsomes by GC-MS and LC-HR-MS/MS techniques and of its detectability by GC-MS or LC-MS(n) standard screening approaches.

  2015cited by this paper
• Pentylindole/Pentylindazole Synthetic Cannabinoids and Their 5-Fluoro Analogs Produce Different Primary Metabolites: Metabolite Profiling for AB-PINACA and 5F-AB-PINACA

  2015influential reference
• 4-Methoxy-α-PVP: in silico prediction, metabolic stability, and metabolite identification by human hepatocyte incubation and high-resolution mass spectrometry

  2015cited by this paper
• High-resolution mass spectrometric metabolite profiling of a novel synthetic designer drug, N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135), using cryopreserved human hepatocytes and assessment of metabolic stability with human liver microsomes.

  2015cited by this paper
• Quantitative urine confirmatory testing for synthetic cannabinoids in randomly collected urine specimens.

  2015influential reference
• Study on the phase I metabolism of novel synthetic cannabinoids, APICA and its fluorinated analogue.

  2015cited by this paper
• Four types of cannabimimetic indazole and indole derivatives, ADB-BINACA, AB-FUBICA, ADB-FUBICA, and AB-BICA, identified as new psychoactive substances

  2015cited by this paper
• CYP3A4 Mediates Oxidative Metabolism of the Synthetic Cannabinoid AKB-48

  2015cited by this paper
• In vitro and in vivo human metabolism of the synthetic cannabinoid AB-CHMINACA.

  2015influential reference
• Identification of AB-FUBINACA metabolites in human hepatocytes and urine using high-resolution mass spectrometry

  2015influential reference
• UPLC/ESI-MS/MS-based determination of metabolism of several new illicit drugs, ADB-FUBINACA, AB-FUBINACA, AB-PINACA, QUPIC, 5F-QUPIC and α-PVT, by human liver microsome.

  2014influential reference
• Determination of major metabolites of MAM-2201 and JWH-122 in in vitro and in vivo studies to distinguish their intake.

  2014cited by this paper
• Lefetamine-derived designer drugs N-ethyl-1,2-diphenylethylamine (NEDPA) and N-iso-propyl-1,2-diphenylethylamine (NPDPA): metabolism and detectability in rat urine using GC-MS, LC-MSn and LC-HR-MS/MS.

  2014cited by this paper
• Nontargeted SWATH acquisition for identifying 47 synthetic cannabinoid metabolites in human urine by liquid chromatography-high-resolution tandem mass spectrometry

  2014cited by this paper
• Changes in the prevalence of new psychoactive substances before and after the introduction of the generic scheduling of synthetic cannabinoids in Japan.

  2014cited by this paper
• Synthetic cannabinoids abused in South Korea: drug identifications by the National Forensic Service from 2009 to June 2013

  2013cited by this paper
• In vivo and in vitro metabolism of the synthetic cannabinoid JWH-200.

  2013cited by this paper
• Studies on the metabolism and detectability of the emerging drug of abuse diphenyl-2-pyrrolidinemethanol (D2PM) in rat urine using GC-MS and LC-HR-MS/MS.

  2013cited by this paper
• First Characterization of AKB-48 Metabolism, a Novel Synthetic Cannabinoid, Using Human Hepatocytes and High-Resolution Mass Spectrometry

  2013cited by this paper
• Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.

  2012cited by this paper
• Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in 'herbal mixtures' using LC-MS/MS techniques.

  2012cited by this paper
• Identification and quantitation of two new naphthoylindole drugs-of-abuse, (1-(5-hydroxypentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone (AM-2202) and (1-(4-pentenyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone, with other synthetic cannabinoids in unregulated “herbal” products circulated in the Tokyo

  2012cited by this paper
• Cytochrome P450-Mediated Oxidative Metabolism of Abused Synthetic Cannabinoids Found in K2/Spice: Identification of Novel Cannabinoid Receptor Ligands

  2012cited by this paper
• Changes in the prevalence of synthetic cannabinoids and cathinone derivatives in Japan until early 2012

  2012cited by this paper
• Detection of urinary metabolites of AM-2201 and UR-144, two novel synthetic cannabinoids.

  2012cited by this paper
• Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls.

  2011cited by this paper
• Detection of JWH-018 metabolites in smoking mixture post-administration urine.

  2010cited by this paper
• The pivotal role of hepatocytes in drug discovery.

  2007cited by this paper
• Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an international expert panel.

  1999cited by this paper

• Spectral trends in DART-MS data obtained from the NIST DART-MS forensics database: A resource for unknown compound classification

  2025cites this paper
• Differential cannabinoid‐like effects and pharmacokinetics of ADB‐BICA, ADB‐BINACA, ADB‐4en‐PINACA and MDMB‐4en‐PINACA in mice: A comparative study

  2024influential citation
• Metabolism of ADB-FUBIATA in zebrafish and pooled human liver microsomes investigated by liquid chromatography-high-resolution mass spectrometry.

  2024cites this paper
• Metabolic profiling of a new synthetic cannabinoid receptor agonist, ADMB-FUBIATA, with human liver microsomes, human primary hepatocytes and human recombinant CYP450 enzymes using LC-quadrupole-orbitrap MS.

  2024cites this paper
• Metabolic characteristic profiling of 1-amino-3,3-dimethyl-1-oxobutan-2-yl-derived indole and indazole synthetic cannabinoids in vitro.

  2024cites this paper
• Metabolism of Six Novel Nitazenes in Human Liver Microsomes Based on Ultra-High-Performance Liquid Chromatography Coupled With High-Resolution Mass Spectrometry.

  2024cites this paper
• In vitro metabolic profiling of new synthetic cannabinoids, ADB-FUBIATA, AFUBIATA, CH-FUBIATA, and CH-PIATA

  2023cites this paper
• Metabolism of four novel structural analogs of ketamine, 2-FXE [2-(ethylamino)-2-(2-fluorophenyl) cyclohexan-1-one], 2-MDCK [2-(methylamino)-2-(o-tolyl) cyclohexan-1-one], 3-DMXE [2-(ethylamino)-2-(m-tolyl) cyclohexan-1-one], and 2-DMXE [2-(ethylamino)-2-(o-tolyl) cyclohexan-1-one], in human liver m

  2023cites this paper
• Detection of ADB-BUTINACA Metabolites in Human Urine, Blood, Kidney and Liver.

  2021cites this paper
• Monitoring metabolism of synthetic cannabinoid 4F-MDMB-BINACA via high-resolution mass spectrometry assessed in cultured hepatoma cell line, fungus, liver microsomes and confirmed using urine samples

  2020cites this paper
• Structure-metabolism relationships of valine and tert-leucine-derived synthetic cannabinoid receptor agonists: a systematic comparison of the in vitro phase I metabolism using pooled human liver microsomes and high-resolution mass spectrometry

  2019cites this paper
• Functional evaluation of carboxy metabolites of synthetic cannabinoid receptor agonists featuring scaffolds based on L-valine or L-tert-leucine.

  2019cites this paper